Brain Injuries: Clinical Trials

47 trials for Brain Injuries, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed. 47 Phase 3, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 347Completed 47
Phase 211Completed 11

Follow Brain Injuries: new trials by email Literature Review of Brain Injuries trials Research Report on Brain Injuries

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury
Memantine Hydrochloride - Treatment of Cognitive Deficits After Traumatic Brain Injury
Phase 3CompletedAssiut University602024-01-012024-08-07
The Effect of Mannitol Volume With Changes in Osmolarity in Traumatic Brain Injury
Mannitol - Anesthesia, Traumatic Brain Injury
Phase 3CompletedUniversitas Diponegoro642023-11-012026-06-11
Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU
Cerebrolysin, amantadine sulfate - Traumatic Brain Injury
Phase 3CompletedAin Shams University1502023-09-012025-11-19
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Routine labs - Hemorrhagic Shock, Acute Blood Loss Anemia
Phase 3CompletedLoma Linda University1992022-03-052025-08-08
NeuroAiD II™ (MLC901) in Mild Traumatic Brain Injury
Traditional Chinese Medicine (NeuroAiD II™ (MLC901), Placebo - Traumatic Brain Injury
Phase 3CompletedMoleac Pte Ltd.1822021-08-232023-03-15
Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury
Vitamin B3, Vitamin B12 - Traumatic Brain Injury
Phase 3CompletedKRL Hospital, Islamabad3002021-06-012023-07-24
International Trial of Efficacy of Cytoflavin in Head Trauma
Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Head Trauma,Closed
Phase 3CompletedPOLYSAN Scientific & Technological Pharmaceutical Company1662020-11-222025-04-18
RECONsolidation of Traumatic Memories to ResOLve Post Traumatic Stress Disorder (RECONTROLPTSD)
Reconsolidation of Traumatic Memories (RTM), Prolonged Exposure (PE) - Posttraumatic Stress Disorder, Traumatic Brain Injury
Phase 2 / Phase 3CompletedUniformed Services University of the Health Sciences942019-06-122025-07-15
Mgso4 as Neuroprotective in Post Traumatic Brain Injury
Magnesium Sulfate, Placebo - Magnesium Sulphate, Traumatic Brain Injury
Phase 3CompletedOsama Mohamed Abdelwahab602019-05-022020-11-30
Inhaled Nitric Oxide in Brain Injury
Inhaled Nitric Oxide, Placebo - Traumatic Brain Injury
Phase 3CompletedUniversity of Cincinnati132018-12-122025-04-30
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
Somatropin - Traumatic Brain Injury, Fatigue
Phase 3CompletedThe University of Texas Medical Branch, Galveston722018-08-062025-03-05
The Effect of Melatonin Administration on Sedation Level as Adjuvant to Propofol
Melatonin 10 MG Oral Tablet, Propofol, Placebo oral tablet - TBI (Traumatic Brain Injury)
Phase 3CompletedCairo University382018-01-012019-07-26
Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury
Salovum, Placebo - Brain Trauma
Phase 3CompletedPeter Siesjö1002017-09-172022-10-12
Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury
VAS203, Saline - Traumatic Brain Injury
Phase 3CompletedveriNOS operations GmbH2242016-06-012021-10-11
Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness
Standard physiotherapy, Erigo®Pro group without FES, Erigo®Pro group with FES - Brain Injuries, Disorders of Consciousness
Phase 3CompletedLudwig-Maximilians - University of Munich472016-01-012019-08-13
Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients
EGCG, Placebo (deionized water) - Traumatic Brain Injury
Phase 2 / Phase 3CompletedNational Nutrition and Food Technology Institute302015-03-012016-06-07
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NT 201 Placebo, NT 201 - Chronic Troublesome Sialorrhea, Cerebral Palsy
Phase 3CompletedMerz Pharmaceuticals GmbH2562015-02-092021-08-10
Safety and Efficacy of Wendan Decoction in Acute Moderated to Severe Brain Injury
Wendan decoction combination in acute brain injury - Acute Brain Injury
Phase 2 / Phase 3CompletedTaichung Tzu Chi Hospital602014-06-012019-02-22
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units), Placebo - Chronic Troublesome Sialorrhea, Parkinson's Disease
Phase 3CompletedMerz Pharmaceuticals GmbH1842014-04-012018-03-27
Multicenter Evaluation of Memory Remediation After TBI With Donepezil
Donepezil, Placebo - Traumatic Brain Injury, Memory Deficits
Phase 3CompletedBaylor College of Medicine752013-09-012025-01-15

Showing 20 of 47. Sign in to see all of them.

Narrower conditions

Brain Injuries, Traumatic (41)  ·  Craniocerebral Trauma (5)  ·  Wounds and Injuries (5)  ·  Cognitive Dysfunction (4)  ·  Stroke (4)  ·  Brain Concussion (3)  ·  Hypothermia (3)  ·  Anxiety Disorders (2)  ·  Consciousness Disorders (2)  ·  Head Injuries, Closed (2)  ·  Parkinson Disease (2)  ·  Adrenal Insufficiency (1)  ·  Alcoholism (1)  ·  Alzheimer Disease (1)

Broader conditions

Brain Diseases (47)  ·  Central Nervous System Diseases (47)  ·  Nervous System Diseases (47)  ·  Trauma, Nervous System (46)  ·  Craniocerebral Trauma (41)  ·  Wounds and Injuries (41)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Mental Disorders (11)  ·  Signs and Symptoms (10)  ·  Neurocognitive Disorders (7)  ·  Cardiovascular Diseases (6)  ·  Vascular Diseases (6)  ·  Cerebrovascular Disorders (5)  ·  Neurologic Manifestations (5)

Interventions

Sodium Chloride (4)  ·  Saline Solution (3)  ·  Amantadine (2)  ·  Botulinum Toxins, Type A (2)  ·  Magnesium Sulfate (2)  ·  Niacinamide (2)  ·  Tranexamic Acid (2)  ·  Valproic Acid (2)  ·  incobotulinumtoxinA (2)  ·  4-amino-tetrahydrobiopterin (1)  ·  Acupuncture Therapy (1)  ·  Cardiopulmonary Resuscitation (1)  ·  Cholinesterase Inhibitors (1)  ·  Cyclosporine (1)  ·  Dextrans (1)

Sponsors

Baylor College of Medicine (2)  ·  Merz Pharmaceuticals GmbH (2)  ·  VA Office of Research and Development (2)  ·  Ain Shams University (1)  ·  Assiut University (1)  ·  Australia and New Zealand Intensive Care Society (1)  ·  Australian and New Zealand Intensive Care Research Centre (1)  ·  Avanir Pharmaceuticals (1)  ·  BHR Pharma, LLC (1)  ·  Cairo University (1)  ·  Claudia Sue Robertson (1)  ·  Columbia University (1)  ·  Emory University (1)  ·  Hospices Civils de Lyon (1)  ·  JFK Medical Center (1)

Countries

United States (19)  ·  Germany (6)  ·  France (5)  ·  Egypt (4)  ·  Russia (4)  ·  Australia (3)  ·  New Zealand (3)  ·  Austria (2)  ·  Canada (2)  ·  Finland (2)  ·  Georgia (2)  ·  Hungary (2)  ·  Poland (2)  ·  Spain (2)  ·  Thailand (2)

Top investigators

Adriaan J Vlok, Professor (1)  ·  Alexander V Savello, Prof (1)  ·  Alistair D Nichol, MD (1)  ·  Allen W Brown, MD (1)  ·  Andreas Bender, Prof.Dr. (1)  ·  Andrew Maas, M.D. (1)  ·  Angelle Sander, PhD (1)  ·  Aria P Hayanto, Sp.An-TI (1)  ·  Avroy A. Fanaroff, MD (1)  ·  Barbara J. Stoll, MD (1)  ·  Barry Willer, Ph.D. (1)  ·  Claudia Robertson, MD (1)

Results publications

PMID 10625862, PMID 12114906, PMID 16361021, PMID 17166799, PMID 19930566, PMID 20082712, PMID 21675055, PMID 22375973, PMID 22446155, PMID 22721545, PMID 23895556, PMID 24686108, PMID 24701988, PMID 24842590, PMID 25058216, PMID 25062507, PMID 25066331, PMID 25493978, PMID 25528574, PMID 25884605, PMID 26452709, PMID 26491799, PMID 26496111, PMID 27433815, PMID 27626622, PMID 27630085, PMID 28716153, PMID 30132785, PMID 30175246, PMID 30184559, PMID 30583957, PMID 30918101, PMID 31623894, PMID 31794936, PMID 31937347, PMID 32711551, PMID 33172504, PMID 33514274, PMID 33566466, PMID 33928903, PMID 34116828, PMID 34213962, PMID 34341153, PMID 35418437, PMID 35461285, PMID 36136523, PMID 36536249, PMID 38325012, PMID 38894576, PMID 39301879

NIH funding

2009 (1), M01RR000070 (1), M01RR000750 (1), M01RR000997 (1), M01RR006022 (1), M01RR008084 (1), P01NS038660 (1), R01NS055827 (1), U01HD019897 (1), U10HD021364 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1)